Aarhus Universitet

Dennis Vestergaard Pedersen

Henrik Pedersen

Steffen Thiel

Rasmus Kjeldsen Jensen

Nick Stub Laursen

Alessandra Zarantonello

Gregers Rom Andersen

Single domain antibodies are provided, which are capable of specifically binding to an epitope of a human complement factor selected from the group consisting of C1q, C3, C4 and/or the proteolytic derivatives C3b and C4b. Further the use of the antibodies are provided for methods in modulating the activity of the complement system as well as methods of treating disorders associated with complement activation.

Bispecific constructs for target and complement engagement

Single domain antibodies are provided, which are capable of specifically binding to an epitope of a human complement factor selected from the group consisting of Cq, C3, C4 and/or the proteolytic derivatives C3b and C4b. Further the use of the antibodies are provided for methods in modulating the activity of the complement system as well as methods of treating disorders associated with complement activation.

Methods of treating complement-mediated disease

Single domain antibodies are provided, which are capable of specifically binding to an epitope of a human complement factor selected from the group consisting of C1q, C3, C4 and/or the proteolytic derivatives C3b and C4b. Further the use of the antibodies are provided for methods in modulating the activity of the complement system as well 5 as methods of treating disorders associated with complement activation.

Growing community of inventors

Aarhus C, Denmark

Dennis Vestergaard Pedersen